Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of GSM-779690T in Healthy Adults
NCT07690228Phase 1Not yet recruiting
- Sponsor
- ACTA Pharmaceuticals
- Start
- Aug 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing Active Drug GSM-779690T with Placebo (2 arms). Primary endpoint: Safety Evaluation at 21 days. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
GSM-779690T
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07690228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07690228.